ArticleThe Journal of infection2022
Persistence at one year of neutralizing antibodies after SARS-CoV-2 infection: Influence of initial severity and steroid use.
Abstract readLetterComment
In one paragraph
Article in The Journal of infection, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Short- and long-term T cell and antibody responses following dexamethasone treatment in COVID-19.JCI insight · 2023Observational
- SARS-CoV-2 anti-spike antibodies after a fourth dose of COVID-19 vaccine in adult solid-organ transplant recipients.Vaccine · 2022Article
- A Cellular Assay for Spike/ACE2 Fusion: Quantification of Fusion-Inhibitory Antibodies after COVID-19 and Vaccination.Viruses · 2022Article
- Detecting SARS-CoV-2 neutralizing immunity: highlighting the potential of split nanoluciferase technology.Journal of molecular cell biology · 2022Review
- Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platform.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- Article
- SARS-CoV-2-Specific Antibody (Ab) Levels and the Kinetic of Ab Decline Determine Ab Persistence Over 1 Year.Frontiers in medicine · 2022Article
- Humoral immune response to SARS-CoV-2 in five different groups of individuals at different environmental and professional risk of infection.Scientific reports · 2021Article
Corrections and comments
- Comment on
Authors and funding
17 authors.
Olivier EpaulardService des Maladies Infectieuses, Center Hospitalier Universitaire Grenoble-Alpes, Grenoble, France; Groupe de Recherche en Infectiologie Clinique CIC-1406, Inserm - CHUGA - Université Grenoble Alpes, Grenoble, France; UMR 5075 - CEA-CNRS-UGA, Institut de Biologie Structurale, Grenoble, France. Electronic address: oepaulard@chu-grenoble.fr.
Marlyse BuissonUMR 5075 - CEA-CNRS-UGA, Institut de Biologie Structurale, Grenoble, France; Laboratoire de Virologie, Center Hospitalier Universitaire Grenoble-Alpes, Grenoble, France.
Benjamin NemozGroupe de Recherche en Infectiologie Clinique CIC-1406, Inserm - CHUGA - Université Grenoble Alpes, Grenoble, France; UMR 5075 - CEA-CNRS-UGA, Institut de Biologie Structurale, Grenoble, France; Laboratoire de Virologie, Center Hospitalier Universitaire Grenoble-Alpes, Grenoble, France.
Marion Le MaréchalService des Maladies Infectieuses, Center Hospitalier Universitaire Grenoble-Alpes, Grenoble, France; Groupe de Recherche en Infectiologie Clinique CIC-1406, Inserm - CHUGA - Université Grenoble Alpes, Grenoble, France.
Nicolas TerziService de Médecine Intensive et Réanimation, Center Hospitalier Universitaire Grenoble-Alpes, Grenoble, France.
Jean-François PayenDépartement d'anesthésie et Réanimation, Center Hospitalier Universitaire Grenoble-Alpes, Grenoble, France.
Marie FroidureService des Maladies Infectieuses, Center Hospitalier Universitaire Grenoble-Alpes, Grenoble, France; Groupe de Recherche en Infectiologie Clinique CIC-1406, Inserm - CHUGA - Université Grenoble Alpes, Grenoble, France.
Myriam BlancService des Maladies Infectieuses, Center Hospitalier Universitaire Grenoble-Alpes, Grenoble, France; Groupe de Recherche en Infectiologie Clinique CIC-1406, Inserm - CHUGA - Université Grenoble Alpes, Grenoble, France.
Anne-Laure MounayarService des Maladies Infectieuses, Center Hospitalier Universitaire Grenoble-Alpes, Grenoble, France; Groupe de Recherche en Infectiologie Clinique CIC-1406, Inserm - CHUGA - Université Grenoble Alpes, Grenoble, France.
Fanny QuénardService des Maladies Infectieuses, Center Hospitalier Universitaire Grenoble-Alpes, Grenoble, France; Groupe de Recherche en Infectiologie Clinique CIC-1406, Inserm - CHUGA - Université Grenoble Alpes, Grenoble, France.
Isabelle PierreService des Maladies Infectieuses, Center Hospitalier Universitaire Grenoble-Alpes, Grenoble, France; Groupe de Recherche en Infectiologie Clinique CIC-1406, Inserm - CHUGA - Université Grenoble Alpes, Grenoble, France.
Patricia PaveseService des Maladies Infectieuses, Center Hospitalier Universitaire Grenoble-Alpes, Grenoble, France; Groupe de Recherche en Infectiologie Clinique CIC-1406, Inserm - CHUGA - Université Grenoble Alpes, Grenoble, France.
Raphaele GermiGroupe de Recherche en Infectiologie Clinique CIC-1406, Inserm - CHUGA - Université Grenoble Alpes, Grenoble, France; UMR 5075 - CEA-CNRS-UGA, Institut de Biologie Structurale, Grenoble, France; Laboratoire de Virologie, Center Hospitalier Universitaire Grenoble-Alpes, Grenoble, France.
Laurence GrossiGroupe de Recherche en Infectiologie Clinique CIC-1406, Inserm - CHUGA - Université Grenoble Alpes, Grenoble, France; UMR 5075 - CEA-CNRS-UGA, Institut de Biologie Structurale, Grenoble, France; Laboratoire de Virologie, Center Hospitalier Universitaire Grenoble-Alpes, Grenoble, France.
Sylvie LarratGroupe de Recherche en Infectiologie Clinique CIC-1406, Inserm - CHUGA - Université Grenoble Alpes, Grenoble, France; UMR 5075 - CEA-CNRS-UGA, Institut de Biologie Structurale, Grenoble, France; Laboratoire de Virologie, Center Hospitalier Universitaire Grenoble-Alpes, Grenoble, France.
Pascal PoignardGroupe de Recherche en Infectiologie Clinique CIC-1406, Inserm - CHUGA - Université Grenoble Alpes, Grenoble, France; UMR 5075 - CEA-CNRS-UGA, Institut de Biologie Structurale, Grenoble, France; Laboratoire de Virologie, Center Hospitalier Universitaire Grenoble-Alpes, Grenoble, France.
Julien LupoGroupe de Recherche en Infectiologie Clinique CIC-1406, Inserm - CHUGA - Université Grenoble Alpes, Grenoble, France; UMR 5075 - CEA-CNRS-UGA, Institut de Biologie Structurale, Grenoble, France; Laboratoire de Virologie, Center Hospitalier Universitaire Grenoble-Alpes, Grenoble, France.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antibodies, NeutralizingCOVID-19Antibodies, ViralHumansSARS-CoV-2SteroidsAntibodies, NeutralizingAntibodies, ViralSteroids
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.